Akebia Therapeutics (AKBA) Assets Average (2014 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Assets Average of $369.5 million for Q1 2026, up 39.23% year-over-year from $265.4 million in Q1 2025, and little changed quarter-over-quarter from $370.4 million in Q4 2025.
Akebia Therapeutics (AKBA) Assets Average (2014 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Assets Average for 13 consecutive years, with $369.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 39.23% year-over-year to $369.5 million; the TTM figure through Mar 2026 stood at $369.5 million (up 39.23% YoY), while the FY2025 annual figure was $298.6 million, up 29.17% from the prior year.
- Assets Average steadied at $369.5 million in Q1 2026 per AKBA's latest filing, from $370.4 million in the prior quarter.
- Across five years, Assets Average topped out at $535.8 million in Q2 2022 and bottomed at $213.7 million in Q3 2024.
- Historically, Assets Average has averaged $329.4 million across 5 years, with a median of $318.5 million in 2023.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 50.11% — and 2025, when it surged 73.14%.
- Akebia Therapeutics' Assets Average stood at $400.2 million in 2022, then plunged by 40.44% to $238.4 million in 2023, then retreated by 10.26% to $213.9 million in 2024, then soared by 73.14% to $370.4 million in 2025, then retreated by 0.22% to $369.5 million in 2026.
- Business Quant data shows AKBA's Assets Average at $369.5 million in Q1 2026, $370.4 million in Q4 2025, and $354.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Akebia Therapeutics | 245.42 Mn | 89.87 Mn | 38.70 Mn | 356.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 356.09 Mn |
| Mar 31, 2026 | 369.54 Mn |
| Dec 31, 2025 | 370.36 Mn |
| Sep 30, 2025 | 354.87 Mn |
| Jun 30, 2025 | 327.89 Mn |
| Mar 31, 2025 | 265.43 Mn |
| Dec 31, 2024 | 213.91 Mn |
| Sep 30, 2024 | 213.67 Mn |
| Jun 30, 2024 | 222.84 Mn |
| Mar 31, 2024 | 233.59 Mn |
| Dec 31, 2023 | 238.35 Mn |
| Sep 30, 2023 | 244.36 Mn |
| Jun 30, 2023 | 267.32 Mn |
| Mar 31, 2023 | 318.49 Mn |
| Dec 31, 2022 | 400.15 Mn |
| Sep 30, 2022 | 487.07 Mn |
| Jun 30, 2022 | 535.84 Mn |
| Mar 31, 2022 | 535.57 Mn |
| Dec 31, 2021 | 565.81 Mn |
| Sep 30, 2021 | 607.07 Mn |